Aim: To compare safety (immunogenicity) and efficacy of GP40061 insulin glargine (GP-Gla)
and Lantus® (Sanofi glargine, Sa-Gla) in people with diabetes mellitus. Materials & methods: This randomized open-label, 26-week clinical trial enrolled 180 Type 1 ...